Second-Line Treatment Options for Myelofibrosis
Second-line therapies for myelofibrosis that are available or in the pipeline for use.
Pharmacotherapy for Myelofibrosis
Circumstances for which hydroxyurea, ruxolitinib, or other therapy may be selected to treat newly diagnosed myelofibrosis.
Stem Cell Transplants in Myelofibrosis
Best practices in determining eligibility and preparing patients with myelofibrosis for allogeneic stem cell transplantation.
Treatment Planning and Myelofibrosis
Characteristics that contribute to treatment decisions for patients with newly diagnosed myelofibrosis
Risk Stratifying Patients With Myelofibrosis
Criteria used to risk stratify and classify patients with newly diagnosed myelofibrosis and establish treatment paradigms.
Symptom Assessments in Myelofibrosis
The most common symptoms that present in patients with newly diagnosed myelofibrosis and variables that factor into initial treatment decisions.
Pathophysiology of Myelofibrosis
The role of signaling pathways, mutations, and alterations in the development of myelofibrosis (MF), and characteristics that distinguish primary MF from secondary MF.
Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid Malignancies
In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.
Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia
In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies.
Novel Agent Active in Refractory Polycythemia Vera
This video highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.
Clarifying the Use of Ruxolitinib in Patients With Myelofibrosis
In this article, we provide updated data on ruxolitinib therapy for patients with myelofibrosis and offer expert opinion on the appropriate use of this agent in the community practice.